Item 2.02 Results of Operations and Financial Condition.

On January 10, 2023, Amarin Corporation plc (the "Company") issued a press release announcing its preliminary 2022 revenue results and year end cash position, and 2023 priorities (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure

The Company will present further details on the matters noted above at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 8:15 p.m. Eastern Time/5:15 Pacific Time, which presentation will be accessible by a live webcast through the Company's website at https://investor.amarincorp.com/events-and-presentations/events. A copy of the Company's investor deck, which will be referenced during the Company's webcast presentation, is furnished herewith as Exhibit 99.2

The information set forth under Item 2.02, Item 7.01, and in the Press Release and the Investor Deck furnished as Exhibit 99.1 and Exhibit 99.2 herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits




(d) Exhibits

Exhibit
  No.       Description

99.1          Press Release, dated January 10, 2023 (furnished herewith)

99.2          Investor Deck dated January 2023

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses